S100B and Parkinson disease: A crucial role of S100B pathogenic processes was confirmed in S100B knockout mice treated with MPTP to induce PD, where the lack of S100B expression was accompanied by amelioration of pathological parameters such as reduced loss of dopaminergic neurons, reduced microgliosis, and reduced expression of tumor necrosis factor (TNF) alpha [27].